When donors give blood, the components of that blood most commonly used by hospitals, red blood cells, are refrigerated and stored for up to six weeks, at which point it’s thought that their ability to transport oxygen becomes depleted. A growing debate, however, has emerged around the age at which blood becomes unsuitable for transfusion. […]
A Michigan company developing a treatment to help restore vision in patients with retinal degeneration hopes to have its lead candidate in clinical trials in 2012. RetroSense Therapeutics, an Ann Arbor startup company, is targeting patients with blindness from retinal pigmentosa (RP) and advanced dry age-related macular degeneration (dry-AMD) for its new therapy derived from […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Hygieia's glucose monitoring system would allow diabetics to adjust the amount of glucose they inject without visiting a doctor. The device provides dose-by-dose insulin recommendations based on their body chemistry as well as a blood sample. The product is called the Diabetes Insulin Guidance System, but is often described as a GPS for diabetes, adjusting someone's diabetes goals the way a GPS guides drivers on the road.
Meditrina, which is based in Ann Arbor, Michigan, is using patents from AstraZeneca to treat women's health issues including endometriosis and uterine fibroids, which are abnormal growths or tumors that can cause pain and infertility. The company has completed Phase II trials on its two drugs - MPI-676 and MPI-674 - which treat endometriosis and abnormal uterine bleeding, respectively.
"We expect that this collaboration will be a critical advantage for Aastrom as we move our cardiovascular programs into the final stages of clinical development," said Aastrom CEO Tim Mayleben in prepared remarks.
Ann Arbor, Michigan, biopharmaceutical company Cerenis Therapeutics added $13.9 million to a July investment round that it will use to continue clinical trials of a drug to treat heart disease. Cerenis will use its latest investment to do Phase II clinical trial development of CER-001, which mimics high-density lipid ("good") cholesterol and can rapidly reverse atherosclerotic plaque.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Compendia Bioscience Inc. in Ann Arbor, Michigan, has won a $1.3 million Small Business Innovation Research Fast Track award to create a way for scientists to survey micro-RNA data across databases.
Two University of Michigan MBA graduates have formed Resonant Venture Partners in Ann Arbor to invest in seed-stage IT, life sciences, advanced manufacturing, alternative energy and defense companies in their state.
Molecular diagnostics startup Swift Biosciences Inc. has pulled in a $3 million Series A investment. The Ann Arbor, Michigan-based company will sell molecular biology reagents, which help scientists and doctors conduct genetic tests to identify whether patients are susceptible to specific diseases. Reagents are chemicals used in lab settings to determine whether a chemical reaction […]
Cerenis Therapeutics has pulled in a $51.7 million Series C round to fund Phase 2 trials of a drug that treats cardiovascular disease. The company, with operations in France and Ann Arbor, Michigan, has now raised $138 million in venture funding since its 2005 inception, according to a statement. (The company listed its funding amounts […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Adeona Pharmaceuticals (AMEX: AEN) has received a $1 million equity investment from a Florida private equity firm as the drug developer looks to bring a drug to market for the first time. The funding comes from the sale of 1.2 million shares to Seaside 88 LP, according to a statement from Adeona. Any source of […]
Plymouth Venture Partners has closed on $16 million and hopes to at least double that amount before it’s done raising cash for its second fund. After the $16 million close was revealed in a regulatory filing, CEO Mark Horne said the company expects to close on another $16 million in the fall and may look […]
CytoPherx Inc. has raised $5 million of an anticipated $7.5 million Series B round to develop a device that filters the blood of kidney disease patients. The funding will go toward a clinical trial of the Ann Arbor, Mich. company’s hollow-fiber dialysis filters, which are used to isolate and deactivate white blood cells in a […]
For MedHub Inc., less is most certainly not more. The company, which sells software to help hospitals manage their residency programs, has made its mark by offering a more robust, far-reaching system than its competitors. With those added features comes a bigger price tag, but that still hasn’t deterred a number of big-name hospitals from […]
Delphinus Medical Technologies Inc. has received $8 million in funding commitments to further develop an ultrasonic breast cancer detection device that could become an alternative to mammograms. The funding means that Delphinus can finally begin the process of commercializing its SoftVue device, which has undergone about 10 years of research and development. Unlike mammography, which […]